SCHEMBL24625446

SCHEMBL24625446

C=C(N)c1sccc1Nc1nc(Cl)ncc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.43
▸ MAPK9 P45984 5/20 0.37
▸ MAPK10 P53779 5/20 0.37
▸ AURKA O14965 2/20 0.36
▸ MAPK8 P45983 3/20 0.35
▸ CDK9 P50750 3/20 0.35
▸ CDK7 P50613 2/20 0.35
▸ ALK Q9UM73 2/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ LTK P29376 1/20 0.35
▸ RPS6KA3 P51812 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ PTK2 Q05397 1/20 0.35
▸ CAMK1D Q8IU85 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ DYRK1B Q9Y463 1/20 0.35
▸ BCL6 P41182 1/20 0.34
▸ CDK2 P24941 3/20 0.34
▸ CDC7 O00311 1/20 0.34
▸ DAPK3 O43293 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24625379 0.87 EGFR (0.45) EGFRMAPK9MAPK10AURKAMAPK8
SCHEMBL18832756 0.83 EGFR (0.46) EGFRMAPK9MAPK10AURKAMAPK8
SCHEMBL29000700 0.80 KMT2A (0.49) EGFRMAPK10
SCHEMBL2061296 0.80 EGFR (0.51) EGFRMAPK9MAPK10MAPK8CDK9
SCHEMBL30379643 0.80 KMT2A (0.49) EGFRMAPK10
SCHEMBL24625596 0.76 CDK9 (0.39) EGFRMAPK9AURKAMAPK8CDK9
SCHEMBL24625390 0.74 MEN1 (0.43) EGFRMAPK9MAPK10MAPK8CDK9
SCHEMBL24625780 0.74 AURKA (0.44) EGFRMAPK10AURKAMAPK8ALK
SCHEMBL24625395 0.74 PKM (0.41) EGFRMAPK10AURKAMAPK8PIM1
SCHEMBL30757908 0.74 MEN1 (0.43) EGFRMAPK9MAPK10MAPK8CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022147620-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-07-14 — — WO disclosed
Send feedback